Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ensysce Biosciences Inc ENSCW


Primary Symbol: ENSC

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Bullboard (NDAQ:ENSC)

View:
Post by whytestockson Feb 06, 2024 11:15pm

Ensysce Biosciences Selected to Present at American Associat

JUST IN: $ENSC Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference~ PF614-MPAR recognized as potential medical breakthrough ~ SAN DIEGO, CA / ACCESSWIRE  ...more  
Post by whytestockson Jan 31, 2024 11:00am

(NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting

Breaking News: $ENSC (NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting2024-01-31 09:03:48 ET DENVER, Colo., Jan. 31, 2023 ( www.247marketnews.com )- Ensysce Biosciences, Inc. (NASDAQ: ENSC) ...more  
Post by whytestockson Jan 23, 2024 10:00am

Ensysce Biosciences Announces FDA Breakthrough Therapy Desig

Just In: $ENSC Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR~ FDA acknowledges significant potential impact of MPAR's oral overdose protection ~ SAN ...more  
Post by Iseneschalon May 10, 2023 8:58am

ENSC.... I have to give kudos to ENSC

I found this Co played by the rules and they were transparent enough to be able to pick spots to enter and exit. Most Co's are the complete opposite Cheers and Good Luck to ENSC !
Post by Iseneschalon May 09, 2023 12:57pm

ENSC....filed yesterday...Check it out!

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716947/000149315223015752
Post by Iseneschalon May 09, 2023 9:38am

ENSC..... Great way to start off the morning ; )

That's a big F'king Cha Ching Sold all into the strength...... I feel confident this will go even higher ...past $7..... Remember...they will want to raise money I bet this will be a double ...more  
Post by Iseneschalon May 09, 2023 9:10am

ENSC.... Seems to me that this should go much higher

Based on past performance..... ENSC traded almost 4.5 million shares on 04/19/23 just on this NR: Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform ...more  
Post by Iseneschalon May 09, 2023 8:45am

ENSC..Great morning Folks...NR and volume/ sh price increase

Cheers !! Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection 2023-05-09 05:02 PT - News Release ~ Represents Major Milestone Towards Launch of ...more  
Post by Iseneschalon Apr 19, 2023 2:13pm

ENSC...... Is that a lil gap down ?

Vols have dried up....share price is getting whack.... Mr. M is licking his chops and laughing all the way to the bank. Now he's sayin..... Anymore weak hands?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities